Clinicians, scientists and public health leaders on the front lines of our response to the COVID-19 pandemic remain eager for new safe and effective therapies to treat the disease. The suffering and loss of life due to COVID-19 are tragic. We empathize with patients and their loved ones and are working to ensure the best care and outcomes for all.
Summarized in this clinical practice guideline are the recommendations for the treatment and management of patients with COVID-19. On February 22, IDSA released a special update alert containing two new recommendations on the use of lopinavir/ritonavir in persons exposed to or with COVID-19.
Join Mark Call, MD, and Amy Strauss of ECG Management Consultants, an industry leader in structuring value-based compensation arrangements, on Feb. 23 at 5 p.m. ET as they discuss the meaning of value-based care and explore the opportunities created by market changes to incorporate value-based arrangements into infectious disease. Register now (member login required).
IDSA’s journals, Clinical Infectious Diseases, The Journal of Infectious Diseases and Open Forum Infectious Diseases, are launching a call for applications for all qualified individuals with interest in joining the journals as associate editors.
IDSA is pleased to announce that Paul E. Sax, MD, FIDSA, has been selected as the next editor-in-chief of Clinical Infectious Diseases. Dr. Sax will succeed Robert T. Schooley, MD, on July 1, 2022, following Dr. Schooley’s years of outstanding service to the journal and the Society.
This educational activity, in partnership with Medscape, will improve the ability of clinicians to implement syndromic testing in the diagnosis and management of gastroenteritis. Faculty include Ferric C Fang, MD and William Greendyke, MD. A maximum of 0.25 AMA PRA Category 1 Credit(s)™ and a maximum of 0.25 ABIM MOC points. Begin the activity. (Login Required)